BREMEN, Germany, Jan. 4, 2017 /PRNewswire/ -- Bruker today
announced the acquisition of SCiLS GmbH in Bremen, Germany. SCiLS develops
innovative software tools such as statistical analysis software,
sophisticated visualization viewers, and secure cloud-based
services for collaborative interpretation of complex mass
spectrometry imaging (MSI) data sets. Financial details were
not disclosed.
Founded as a spin-off from the University of Bremen, the SCiLS founders have research
backgrounds in mathematics, biochemistry, and informatics,
positioning SCiLS to offer software tools that translate complex,
data-rich mass spectrometry images to accessible information.
Currently, 95% of all MSI data is acquired by label-free MALDI
imaging systems. The combination of
SCiLS™ software and MALDI imaging
systems like the Bruker rapifleX™
high-resolution MALDI-TOF(/TOF), and the
solariX™ XR
extreme-resolution MALDI-FTMS, expand the scope of MSI from
life-science research to pharmaceutical applications with the
Molecular Drug Imager
Solution™, and to translational pathology
research with the MALDI
Tissuetyper™.
SCiLS software provides advanced tools for data handling and
computational analysis of multiple data sets, including full sample
cohorts. It provides instant visualization of m/z based image
analysis, including edge-preserving image de-noising and automatic
hotspot removal, automated spatial segmentation for annotation of
features, pattern extraction, and building classifying models based
on training data and classification of new samples. Recently,
SCiLS introduced SCiLS Cloud, where results can be
shared and viewed with a web browser through secure access,
facilitating collaborative research on a global basis. The
SCiLS products SCiLS Lab, SCiLS Lab 3D,
and SCiLS Cloud support MALDI high-resolution data
sets, enabling scientists to gain new insights into the spatial
distribution of small molecules, metabolites, lipids, proteins and
glycans from formalin fixed paraffin embedded (FFPE) or
fresh-frozen tissue samples. SCiLS enables comparative
analytics for finding biomarkers that discriminate
pathophysiological regions (disease, disease adjacent, healthy),
and the determination of molecular margins. Feature
extraction techniques make it simple to compare MSI data to
conventional H&E-stained FFPE tissue.
Professor Peter Maass, Professor
Theodore Alexandrov and Dr.
Dennis Trede, the founders of SCiLS,
commented: "We are very pleased by the evolution of SCiLS, and now
that SCiLS is a part of Bruker's global infrastructure it will make
mass spec-based imaging more accessible. SCiLS has always
been a dynamic, innovation-driven company creating computational
tools required for the molecular interpretation of MSI data, with
the ultimate aim to bridge the gap between advanced research and
routine applications. As MSI is rapidly advancing in multiple
application areas, we believe SCiLS has set the stage for becoming
the de facto standard for mass spectrometry imaging
software."
Dr. Rohan Thakur, Executive Vice
President at Bruker Daltonics, added: "The combination of the
advanced SCiLS software tools coupled with the power of Bruker's
high-resolution MALDI imaging systems is an exciting
development. Our goal is to advance the MSI field and enable
a deeper understanding of the spatial distribution of various
molecules in the disciplines of biomarker discovery, pharma drug
tissue distribution studies, all the way to translational research
in anatomical pathology and future diagnostic applications."
About the Bruker Molecular Drug Imager
Solution
The Molecular Drug Imager Solution
makes full use of the solariX XR extreme resolution
(10 million mass resolution), enabling scientists to see vital
information that is missing in data from other types of mass
spectrometers. Based on Bruker's unique
Paracell™ 7T FTMS technology,
this unique solution enables determination of pharmaceutical drug
tissue distribution in support of ADMET studies. The value of
extreme resolution is the unmatched confidence for label-free drug
and metabolite identification with isotope fine structure (IFS)
confirmation. The FTMS-based Molecular Drug Imager
Solution facilitates seamless workflows for spatial
localization of small molecules in tissue imaging
studies.
About the Bruker MALDI Tissuetyper
The MALDI Tissuetyper solution uses MALDI-TOF
imaging, which is complementary to traditional imaging technologies
in histology. The MALDI Tissuetyper allows
pathologists a fast identification of lipids, peptides and proteins
in tissue samples. In contrast to traditional histological
tissue analysis, the MALDI Tissuetyper requires
neither a molecular probe nor an antibody. The MALDI
Tissuetyper offers multiplex analysis of potential
biomarkers in an untargeted approach. Identification of
protein profiles can lead to the discovery of tumor biomarkers for
future diagnostic and treatment monitoring strategies. The
MALDI Tissuetyper provides complementary information
to immunohistochemistry (IHC) and in many cases can differentiate
cell populations that cannot be differentiated by IHC. It can
save valuable biopsy material in cases where only limited tissue
sample is available. The MALDI Tissuetyper can be
used for biomarker discovery studies, and for multi-marker
tissue-typing and classification. The MALDI
Tissuetyper is currently available for research use
only.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Investor
Contact:
|
Media
Contact:
|
Miroslava
Minkova
|
Dr. Petra
Scheffer
|
Bruker Head of
Investor Relations
|
Bruker Daltonics
Director of MarCom
|
T: +1 (978) 663–3660,
ext. 1479
|
T: +49 421 2205
2843
|
E:
miroslava.minkova@bruker.com
|
E:
petra.scheffer@bruker.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-scils-gmbh-to-advance-maldi-imaging-software-solutions-for-life-science-pharma-and-pathology-research-applications-300385179.html
SOURCE Bruker Corporation